News & Updates

Among patients with paroxysmal atrial fibrillation (AF), initial treatment with cryoballoon ablation reduced the incidence of persistent AF through 3 years of follow-up compared with antiarrhythmic drug (AAD) therapy, according to the PROGRESSIVE-AF* trial presented at AHA 2022.

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.

Monitoring of anti-Xa levels appears beneficial in evaluating current drug concentrations, ensuring immediate safety of therapy, and guiding possible clinical interventions, according to a study.

In the second interim analysis of the PEARLS/KEYNOTE-091 study, adjuvant pembrolizumab monotherapy provided a clinically meaningful improvement in disease-free survival (DFS) in individuals with stage IB–IIIA non-small cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy (CT).

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.